Human Molecular Genetics, 2001, Vol. 10, No. 14 1449-1454
© 2001 Oxford University Press
Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers
Howard Hughes Medical Institute and Department of Biochemistry, Department of Genetics and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA and 1Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
Received January 31, 2001; Revised and Accepted May 10, 2001.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
The 5' untranslated CGG repeat in the fragile X mental retardation-1 (FMR1) gene is expanded in families with fragile X syndrome, with more than 200 CGGs resulting in mental retardation due to the absence of the encoded fragile X mental retardation protein (FMRP). Intermediate and premutation alleles, containing between approximately 40 and 200 repeats, express grossly normal FMRP levels and such carriers are widely believed to be non-penetrant, despite continued reports of subtle cognitive/psychosocial impairment and other phenotypes. Using a highly sensitive quantification assay, we demonstrate significantly diminished FMRP levels in carriers, negatively correlated with repeat number. Despite reduced FMRP, these carrier alleles overexpress FMR1, resulting in a positive correlation between repeat number and FMR1 message level. These biochemical deviations associated with intermediate and premutation FMR1 alleles, found in
4% of the population, suggest that the phenotypic spectrum of fragile X syndrome may need to be revisited. |
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
The fragile X mental retardation protein (FMRP) is a selective RNA-binding protein (1) which is necessary for normal cognitive function, as the lack of FMRP results in mental retardation as a component of the fragile X syndrome. FMRP shuttles between the cytoplasm and the nucleus (2), although at steady-state it is predominantly located in the cytoplasm where it is bound to mRNAs (3) and associates with translating polyribosomes (3). The fragile X mental retardation gene (FMR1) contains a polymorphic trinucleotide CGG repeat tract in the 5'-untranslated region (5'-UTR) of the FMR1 message, with the most common normal allele containing 30 repeats. The vast majority of fragile X cases are the result of a large expansion in the CGG tract (more than 200 repeats), called full mutation alleles. Full mutations abolish FMR1 transcription (4), and the consequent lack of protein product, FMRP, results in fragile X syndrome. Carriers have alleles containing approximately 60–200 repeats, referred to as premutations. Premutation alleles are a functional category, defined by their propensity to change repeat number upon transmission to offspring. This change is particularly significant in the offspring of female premutation carriers, who are at risk of inheriting an expanded, full mutation-length allele. Because of the dynamic relationship between premutation and full mutation alleles, males may be obligate carriers based on their position in their family, but not affected with fragile X syndrome if they are carriers of premutation-length alleles. Recently, an additional category of high-end normal alleles of approximately 40–60 repeats, referred to as intermediate alleles, has been suggested based on evidence suggestive of a mild phenotype (5,6).
The mental retardation associated with fragile X syndrome ranges from mild to severe, and patients present with subtle but characteristic somatic signs, such as prominent ears, prominent mandible, long face and macro-orchidism (7). Although fragile X patients do not typically meet the diagnostic criteria for autism (8,9), many have autistic-like features such as repetitive motor mannerisms, impaired verbal communication and gaze aversion (8,10–12). Social anxiety and shyness are also prevalent (13,14).
While carriers of intermediate-length and premutation alleles are widely regarded as normal in terms of cognitive function (6,15–19), there have been persistent reports of subtle fragile X-like features in premutation carriers, including social anxiety (15,18,19–21), affective disorder (22), obsessive-compulsive disorder (23) and prominent ears (22,24–26). Furthermore, recent studies demonstrate an increased prevalence of intermediate-length (40–60) alleles in the special needs population, suggesting that these FMR1 alleles may also be associated with a mild fragile X-like phenotype (27,28). Ovarian dysfunction, including premature menopause, also occurs at a substantially increased frequency in premutation carrier females, although paradoxically does not appear in women carrying full mutations (29–32).
With the notable exception of ovarian dysfunction, many of the phenotypes reported for premutation and intermediate allele carriers appear as more subtle versions of the fragile X phenotype caused by the total lack of FMRP. Thus, it is reasonable to predict that decreased levels of FMRP are responsible for these subtle features. However, most studies have found FMRP at grossly normal levels in carriers, although a few reports, using non-quantitative methods, have noted occasional FMRP reduction in premutation carriers, most often with large premutations, repeat-length mosaicism, and associated with cognitive impairment (33–36). To explore the relationship between FMR1 repeat number and phenotype, we developed a quantitative assay for the accurate measurement of FMRP levels in cells and found diminished FMRP levels over a very broad range of CGG repeat lengths.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
Using purified FMRP (1) and purified eIF4E (37) as standards, we developed a slot-blot-based assay for the accurate measurement of FMRP levels in cell lysates (Fig. 1). eIF4E is the rate-limiting factor in eukaryotic translation initiation (38,39). In Epstein–Barr virus (EBV)-transformed human male B lymphoblastoid cell lines, we find with this assay 1.10 x 106 molecules of FMRP per cell (n = 7, SD = 0.19 x 106) and 5.35 x 106 molecules of eIF4E per cell (n = 7, SD = 0.81 x 106). As this assay was able to achieve a higher level of sensitivity for FMRP measurement than was previously possible, we re-analyzed the level of this protein relative to the FMR1 CGG repeat tract length in lymphoblastoid cells. The molar ratio of FMRP:eIF4E for male cells containing single FMR1 alleles (due to X chromosome linkage) with 19–35 CGG repeats was 0.218 (SE = 0.009, n = 7). In comparison, two males, reportedly penetrant with mild mental retardation, carrying 140 and 190 CGG repeats exhibited a molar ratio of 0.128 (SE = 0.002), demonstrating a highly significant (t = 6.8254, P < 0.005) 40% reduction of FMRP level compared to males with CGG repeat numbers in the normal range.
|
To examine the relationship between FMRP level and CGG repeat number in smaller premutation alleles, we determined FMRP levels in four premutation males with alleles containing 105–130 repeats. Compared to cells containing normal alleles, a 22% reduction in FMRP was observed relative to the control protein eIF4E (FMRP:eIF4E ratio = 0.171, SE = 0.004), a significant reduction (t = 3.22, P < 0.01). Furthermore, two males with alleles containing intermediate repeat numbers, 48 and 55 CGG repeats, below the length normally considered a premutation, showed a 17% reduction of FMRP when compared with males with normal alleles (t = 2.12, P = 0.05), suggesting that even within this intermediate range, FMRP levels may be affected. As illustrated in Figure 2, these data suggest that FMRP levels are negatively correlated with repeat numbers over a wide range of repeat tract lengths.
|
If the reduction in FMRP levels reported here over a wide range of CGG repeat lengths is biologically relevant, we should be able to detect proportionally increased FMR1 mRNA levels due to the transcriptional compensation mechanism proposed by Tassone et al. (40). We therefore examined FMR1 mRNA levels using reverse trancriptase PCR in the same cells in which we measured FMRP levels (Fig. 3). Normalizing to the amount of X chromosome-linked HPRT mRNA, normal cells had an FMR1 transcript level of 0.89 (SE = 0.098, n = 7). Cells carrying intermediate repeat-length alleles and premutation alleles displayed ratios increased 1.4- and 2.3-fold relative to normal cells (1.29, SE = 0.040, n = 2 and 2.07, SE = 0.313, n = 4, respectively). The two cell lines carrying 140 and 190 repeats exhibited an FMR1 transcript level of 2.33 (SE = 0.785), although these two samples varied considerably (ratios of 1.54 and 3.11, respectively). However, taken together, these data demonstrate a positive correlation between FMR1 transcript levels and repeat number (R = 0.87) which parallels the inverse correlation between repeat length and FMRP levels (R = –0.84).
|
It is unclear if the cell senses diminished FMRP in order to signal the transcriptional enhancement of FMR1 or if the changes in transcription and translation are uncoupled events linked independently to repeat number. To address whether or not the cell senses FMRP function, we quantified the FMR1 mRNA level in cells derived from a mentally retarded male with a normal CGG repeat length but harboring an I304N point mutation in FMR1 (41). This single amino acid change does not change the abundance of the mutant FMRP in the cells (3). However, unlike normal FMRP, which is largely associated with translating ribosomes at steady state, the I304N protein does not detectably associate with ribosomes and remains in the cytoplasm as an mRNP particle (3). The later observation has been taken as evidence for the critical role of the FMRP:ribosome association as this patient has a particularly severe form of fragile X syndrome. Therefore, if the cells sensed FMRP function, these cells would be expected to have altered FMR1 message levels. Analysis of I304N cells indicated that the FMR1 transcript level falls well within the normal range defined above with an FMR1 mRNA level of 1.01. Thus, assuming function is abrogated in these mutant cells, the transcriptional changes reported above do not seem to arise by a graded loss of FMRP function.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
The important role of FMRP in cognitive function is manifest by the mental retardation arising in its absence. As a corollary, it is logical that the subtle fragile X-like cognitive, psychosocial and physical phenotypes associated with some premutation-length alleles may be due to decreased levels of FMRP. While most studies have failed to detect differential FMRP levels associated with premutation-length CGG tracts, reductions in FMRP levels have been observed previously in some mildly impaired premutation carriers. However, the available non-quantitative methods lacked the sensitivity to detect more subtle reductions that might be associated with smaller alleles. As a consequence, it was unclear whether the reduced FMRP levels in affected patients represented part of a linear relationship between FMRP level and repeat number or are a consequence of exceeding an abrupt threshold of repeat number. To address these issues, we developed a sensitive, slot-blot-based assay for the accurate measurement of FMRP levels in cells.
The development of an immunoassay for FMRP that is sensitive in the nano- to picogram range has allowed FMRP levels to be determined in cells with different CGG repeat numbers in the FMR1 mRNA. Cells with CGG repeat numbers in the normal range demonstrated relatively little variance in FMRP levels, suggesting that FMRP levels are tightly regulated in these cells. Furthermore, FMRP was present at molar concentrations that were approximately one-fifth of the rate-limiting factor in translation initiation, eIF4E (38). This is consistent with the model that FMRP is associated with only a subset of mRNAs and ribosomes, rather than being a more general translation factor (42).
This report of a significant and inverse correlation between FMRP level and repeat number indicates that the FMR1 repeat lengths that influence FMRP levels are substantially broadened. Given the earlier reports of behavioral disturbances in premutation carriers and the more recent development indicating that premutations and intermediate FMR1 alleles are found in excess among school children requiring special needs, the findings reported here of significant reductions of FMRP in these repeat lengths is consistent with penetrance in some such individuals with a more subtle cognitive and behavioral phenotype than seen in typical fragile X syndrome. Given that such phenotypes are not consistently observed in all carriers, there may be modifying loci operating epistatically with intermediate or premutation FMR1 alleles generating reduced FMRP levels. The observation of reduced FMRP relative to the FMR1 CGG repeat length is also consistent with the model put forth by Feng et al. (43). Using less quantitative FMRP measurements than used here, Feng et al. (43) showed that when the CGG repeat in the 5'-UTR of the FMR1 mRNA exceeds 200 repeats, the 40S ribosomal subunit is impeded in scanning for the downstream initiation codon, resulting in translational vicissitude and consequent FMRP reduction (43). Here, it is likely that this same mechanism is responsible for the more subtle reductions of FMRP observed in the smaller allele repeat lengths. Indeed, Tassone et al. (35) recently reported that for FMR1 repeat lengths ranging from 55 to 190 triplets, there was a significant increase in FMR1 mRNA levels relative to normal controls and interpreted these data as due to transcriptional compensation for decreased translatability due to the lengthening repeat (40). Although Tassone et al. (36) used an indirect measurement of FMRP levels determined as the percentage of histochemically FMRP-positive cells, they also obtained data suggesting that repeats in excess of 100 triplets were associated with a reduction in the percentage of histochemically FMRP-positive cells. Moreover, our replication of the data of Tassone et al. (35) suggests that the increased abundance of FMR1 message among premutation alleles may be an explanation for the paradoxical occurrence of ovarian failure in female premutation carriers that is not observed among female full mutation carriers (29–32). The consequence of the excess FMR1 message is not clear, but possible mechanisms include acting as a sink for CGG repeat binding mRNA-binding protein(s). The near linear relationships of both FMRP and FMR1 mRNA with CGG repeat number result in tight regulation of FMR1 transcription and FMRP abundance, where the latter parameter, based on Feng et al. (43), is influenced by the translational impediment posed by the 5' untranslated trinucleotide repeat of the FMR1 message. The mechanism at work here is unknown, although the normal FMR1 mRNA level of the mutant I304N cell line, reported here and by others (44), appears to rule out the function of FMRP as a factor, as the I304N FMRP protein is present in normal levels while its lack of function does not result in increased FMR1 transcription. We cannot rule out that the cell directly senses the FMR protein. However, there are data indicating that the I304N protein assumes a less folded conformation (45) and may not interact with its normal protein partners (46). Thus, it is also possible that non-FMRP mechanisms are responsible for the increased FMR1 mRNA levels associated with increased CGG tract lengths, such as the expanded CGG tract leading to proportionally more open promoter conformation and proportionally enhanced transcription, as has been suggested by Raca et al. (47). Independently, the lengthened CGG tract in the 5'-UTR of the message could slow translation, leading to diminished FMRP levels and an apparent coupling of transcription/translation with repeat length. Additional studies of FMR1 mRNA levels in conjunction with methylation and histone acetylation analyses in the repeat range between hyper-transcribed premutations and hypo-transcribed full mutations may be useful in elucidation of these molecular mechanisms. Regardless of the precise mechanism, the concomitant increase in FMR1 transcript levels over a range of increasing repeat tract sizes, including both intermediate and premutation alleles, indicates the existence of a coupled or uncoupled compensatory response to decreased FMRP levels. The compensation is only partial, however, as normal FMRP levels are not achieved in cells with repeat numbers out of the normal range.
Whether or not these drops in FMRP level influence the phenotype of carriers of intermediate and premutation alleles remains to be established and is not addressed here. However, while the number of samples presented here is small, the data reported above provide preliminary evidence for a molecular basis for the cognitive, psychological and somatic features that are sometimes observed in premutation carriers. Current techniques such as western blot analysis and assessments of immuno-positive cell frequencies in blood and hair roots are rapid and useful for biologically-relevant samples. However, the low sensitivity and indirect nature of these techniques, respectively, can be augmented by the quantitative and sensitive immuno-assay presented here. Moreover, this assay may prove valuable in the study of females carrying either premutation or full mutation alleles. Further adaptation of the technique to whole blood, particularly the extension to a sandwich ELISA assay for blood, will be required for large-scale use. However, the data reported now allow an approach to allow investigation of the entire spectrum of phenotypes ranging from fragile X syndrome as the most severe and to more subtle phenotypes, such as learning disabilities, which have recently been suggested to be associated with intermediate-length alleles, which may comprise as many as 4% of FMR1 alleles in the population.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
FMRP quantification
EBV-transformed human B lymphoblastoid cells were lyzed in cold RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.5, 2 mM EDTA, 0.5% Igepal, 0.1% SDS, 0.5% Triton X-100, 0.012 mM deoxycholic acid), boiled for 10 min, cooled on ice and sonicated. Protein concentrations were determined by Bradford assay. Cell extracts, purified FMRP (1) and purified eIF4E (37) were diluted to working concentrations in PBS, or PBS plus 300 mM NaCl for FMRP, and blotted onto nitrocellulose membrane using a Bio-Rad slot-blot apparatus. Proteins were detected using standard immunodetection technology with the anti-FMRP monoclonal antibody 1C3 (48), anti-eIF4E monoclonal antibody (Transduction Laboratories) and HRP-conjugated goat anti-mouse antibody (Kirkegaard and Perry Laboratories) at saturating concentrations. Signals were generated by Enhanced Chemi Luminescence (Amersham) and detected by exposure to Hyperfilm (Amersham). Signal intensities were quantified by analysis of digital scans using the NIH Image 1.62b7f software to plot signal profiles, and areas under the plot profile were used as signal intensities. Molarity of FMRP or eIF4E in the cell lysates was determined using standard curves generated from the purified proteins, after subtracting out signals from the background and secondary antibody controls as appropriate. Calculations of cellular content of FMRP and eIF4E were based on a cell content of 106 picograms of total protein per cell as determined in our laboratory for these cell lines. Each sample was assayed a minimum of three times.
FMR1 mRNA quantification
RNA was extracted from cells with the High Pure RNA Isolation Kit (Roche). RT–PCR of FMR1 and HPRT mRNA was performed on a Roche Light Cycler using the SYBR Green I RNA Amplification Kit (Roche). Primers 5'-gatgaagatacctgcacatttc-3' and 5'-tagctccaatctgtcgcaactgc-3' were used for FMR1, and primers 5'-ctggggtccttttcaccagcaag-3' and 5'-aattatggacaggactgaacgtc-3' were used for HPRT. Annealing temperatures for the RT–PCR reactions were 60° and 62°C, respectively. Melting curve analysis was used to determine the amount of RT–PCR product [change in fluorescence (fluorimeter gain = 5) per change in temperature at 82°C for FMR1 and 85°C for HPRT (DF/DT°C)]. Standard curves were generated from the DF/DT°C for 10–40 ng of RNA template from the normal cell line J1 (containing 29 repeats). Twenty to twenty-five nanograms of template from the other cell lines were amplified, and product level determined relative to that of J1.
|
ACKNOWLEDGEMENTS |
|---|
We thank Stephanie Sherman at Emory University and Flora Tassone and Paul Hagerman at the University of Colorado, Denver, for cell lines and helpful discussion. This project was supported, in part, by NIH grants R37HD20521 and PO1HD35576 to S.T.W. who is also an Investigator with the Howard Hughes Medical Institute.
|
FOOTNOTES |
|---|
+ To whom correspondence should be addressed at: Howard Hughes Medical Institute, Emory University School of Medicine, 1510 Clifton Road, Room 4035, Rollins Research Center, Atlanta, GA 30322, USA. Tel: +1 404 727 5979; Fax: +1 404 727 5408; Email: swarren@emory.edu
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTION RESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
1 Brown, V., Small, K., Lakkis, L., Feng, Y., Gunter, C., Wilkinson, K.D. and Warren, S.T. (1998) Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J. Biol. Chem., 273, 15521–15527.
2 Eberhart, D.E., Malter, H.E., Feng, Y. and Warren, S.T. (1996) The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet., 5, 1083–1091.
3 Feng, Y., Absher, D., Eberhart, D.E., Brown, V., Malter, H.E. and Warren, S.T. (1997) FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell, 1, 109–118.[Web of Science][Medline]
4 Pieretti, M., Zhang, F.P., Fu, Y.U., Warren, S.T., Oostra, B.A., Caskey, C.T. and Nelson, D.L. (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66, 817–822.[Web of Science][Medline]
5 Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick, R.G.,Jr, Warren, S.T. et al. (1991) Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell, 67, 1047–1058.[Web of Science][Medline]
6 Snow, K., Doud, L.K., Hagerman, R., Pergolizzi, R.G., Erster, S.H. and Thibodeau, S.N. (1993) Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am. J. Hum. Genet., 53, 1217–1228.[Web of Science][Medline]
7 Warren, S.T. and Nelson, D.L. (1994) Advances in molecular analysis of fragile X syndrome. J. Am. Med. Assoc., 271, 536–542.
8 Fisch, G.S. (1992) Is autism associated with the fragile X syndrome? Am. J. Med. Genet., 43, 47–55.[Web of Science][Medline]
9 Fisch, G.S., Holden, J.J., Simensen, R., Carpenter, N., Howard-Peebles, P.N., Maddalena, A., Sandgrund, A., Jacques, J.R. and McGann, B. (1994) Is fragile X syndrome a pervasive developmental disability? Cognitive ability and adaptive behavior in males with the full mutation. Am. J. Med. Genet., 51, 346–352.[Web of Science][Medline]
10 Brown, W.T., Jenkins, E.C., Friedman, E., Brooks, J., Wisniewski, K., Raguthu, S. and French, J. (1982) Autism is associated with the fragile-X syndrome. J. Autism Dev. Disord., 12, 303–308.[Web of Science][Medline]
11 Brown, W.T., Friedman, E., Jenkins, E.C., Brooks, J., Wisniewski, K., Raguthu, S. and French, J.H. (1982) Association of fragile X syndrome with autism. Lancet, 1, 100.[Web of Science][Medline]
12 Reiss, A.L. and Freund, L. (1990) Fragile X syndrome, DSM-III-R, and autism. J. Am. Acad. Child Adolesc. Psychiatry, 29, 885–891.
13 Reiss, A.L., Hagerman, R.J., Vinogradov, S., Abrams, M. and King, R.J. (1988) Psychiatric disability in female carriers of the fragile X chromosome. Arch. Gen. Psychiatry, 45, 25–30.
14 Freund, L.S., Reiss, A.L. and Abrams, M.T. (1993) Psychiatric disorders associated with fragile X in the young female. Pediatrics, 91, 321–329.
15 Franke, P., Maier, W., Hautzinger, M., Weiffenbach, O., Gansicke, M., Iwers, B., Poustka, F., Schwab, S.G. and Froster, U. (1996) Fragile-X carrier females: evidence for a distinct psychopathological phenotype? Am. J. Med. Genet., 64, 334–339.[Web of Science][Medline]
16 Rousseau, F., Heitz, D., Biancalana, V., Blumenfeld, S., Kretz, C., Boue, J., Tommerup, N., Van Der Hagen, C., DeLozier-Blanchet, C., Croquette, M.F. et al. (1991) Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N. Engl. J. Med., 325, 1673–1681.[Abstract]
17 Rousseau, F., Heitz, D., Tarleton, J., MacPherson, J., Malmgren, H., Dahl, N., Barnicoat, A., Mathew, C., Mornet, E., Tejada, I. et al. (1994) A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2, 253 cases. Am. J. Hum. Genet., 55, 225–237.[Web of Science][Medline]
18 Sobesky, W.E., Pennington, B.F., Porter, D., Hull, C.E. and Hagerman, R.J. (1994) Emotional and neurocognitive deficits in fragile X. Am. J. Med. Genet., 51, 378–385.[Web of Science][Medline]
19 Thompson, N.M., Gulley, M.L., Rogeness, G.A., Clayton, R.J., Johnson, C., Hazelton, B., Cho, C.G. and Zellmer, V.T. (1994) Neurobehavioral characteristics of CGG amplification status in fragile X females. Am. J. Med. Genet., 54, 378–383.[Web of Science][Medline]
20 Franke, P., Leboyer, M., Gansicke, M., Weiffenbach, O., Biancalana, V., Cornillet-Lefebre, P., Croquette, M.F., Froster, U., Schwab, S.G., Poustka, F. et al. (1998) Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res., 80, 113–127.[Web of Science][Medline]
21 Sobesky, W.E., Hull, C.E. and Hagerman, R.J. (1994) Symptoms of schizotypal personality disorder in fragile X women. J. Am. Acad. Child. Adolesc. Psychiatry, 33, 247–255.[Web of Science][Medline]
22 Sobesky, W.E., Taylor, A.K., Pennington, B.F., Bennetto, L., Porter, D., Riddle, J. and Hagerman, R.J. (1996) Molecular/clinical correlations in females with fragile X. Am. J. Med. Genet., 64, 340–345.[Web of Science][Medline]
23 Dorn, M.B., Mazzocco, M.M. and Hagerman, R.J. (1994) Behavioral and psychiatric disorders in adult male carriers of fragile X. J. Am. Acad. Child Adolesc. Psychiatry, 33, 256–264.[Web of Science][Medline]
24 Hull, C. and Hagerman, R.J. (1993) A study of the physical, behavioral, and medical phenotype, including anthropometric measures, of females with fragile X syndrome. Am. J. Dis. Child, 147, 1236–1241.
25 Loesch, D.Z., Hay, D.A. and Mulley, J. (1994) Transmitting males and carrier females in fragile X–revisited. Am. J. Med. Genet., 51, 392–399.[Web of Science][Medline]
26 Riddle, J.E., Cheema, A., Sobesky, W.E., Gardner, S.C., Taylor, A.K., Pennington, B.F. and Hagerman, R.J. (1998) Phenotypic involvement in females with the FMR1 gene mutation. Am. J. Ment. Retard., 102, 590–601.[Web of Science][Medline]
27 Murray, A., Youings, S., Dennis, N., Latsky, L., Linehan, P., McKechnie, N., Macpherson, J., Pound, M. and Jacobs P. (1996) Population screening at the FRAXA and FRAXE loci: molecular analyses of boys with learning difficulties and their mothers. Hum. Mol. Genet., 5, 727–735.
28 Youings, S.A., Murray, A., Dennis, N., Ennis, S., Lewis, C., McKechnie, N., Pound, M., Sharrock, A. and Jacobs, P. (2000) FRAXA and FRAXE: the results of a five year survey. J. Med. Genet., 37, 415–421.
29 Cronister, A., Schreiner, R., Wittenberger, M., Amiri, K., Harris, K. and Hagerman, R.J. (1991) Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am. J. Med. Genet., 38, 269–274.[Web of Science][Medline]
30 Schwartz, C.E., Dean, J., Howard-Peebles, P.N., Bugge, M., Mikkelsen, M., Tommerup, N., Hull, C., Hagerman, R., Holden, J.J. and Stevenson, R.E. (1994) Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am. J. Med. Genet., 51, 400–402.
31 Allingham-Hawkins, D.J., Babul-Hirji, R., Chitayat, D., Holden, J.J., Yang, K.T., Lee, C., Hudson, R., Gorwill, H., Nolin, S.L., Glicksman, A. et al. (1999) Fragile X premutations is a significant risk factor for premature ovarian failure: The international collaborative POF in fragile X study – preliminary data. Am. J. Med. Genet., 83, 322–325.[Web of Science][Medline]
32 Uzielli, M.L., Guarducci, S., Lapi, E., Cecconi, A., Ricci, U., Ricotti, G., Biondi, C., Scarselli, B., Vieri, F., Scarnato, P. et al. (1999) Premature ovarian failure (POF) and fragile X premutation females: From POF to fragile X carrier identification, from fragile X carrier diagnosis to POF association data. Am. J. Med. Genet., 84, 300–303.[Web of Science][Medline]
33 Hagerman, R.J., Staley, L.W., O’Conner, R., Lugenbeel, K., Nelson, D., McLean, S.D. and Taylor, A. (1996) Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics, 97, 122–126.
34 Kaufmann, W.E., Abrams, M.T., Chen, W. and Reiss, A.L. (1999) Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am. J. Med. Genet., 83, 286–295.[Web of Science][Medline]
35 Tassone, F., Hagerman, R.J., Ikle, D.N., Dyer, P.N., Lampe, M., Willemsen, R., Oostra, B.A. and Taylor, A.K. (1999) FMRP expression as a potential prognostic indicator in fragile X syndrome. Am. J. Med. Genet., 84, 250–261.[Web of Science][Medline]
36 Tassone, F., Hagerman, R.J., Taylor, A.K., Mills, J.B., Harris, S.W., Gane, L.W. and Hagerman, P.J. (2000) Clinical involvement and protein expression in individuals with the FMR1 premutation. Am. J. Med. Genet., 91, 144–152.[Web of Science][Medline]
37 Hagedorn, C.H., Spivak-Kroizman, T., Friedland, D.E., Goss, D.J. and Xie, Y. (1997) Expression of functional eIF4E human: Purification, detailed characterization, and its use in isolating eIF-4e binding proteins. Protein Expr. Purif., 9, 53–60.[Web of Science][Medline]
38 Duncan, R. and Hershey, J.W. (1983) Identification and quantitation of levels of protein synthesis initiation factors in crude HeLa cell lysates by two-dimensional polyacrylamide gel electrophoresis. J. Biol. Chem., 258, 7228–7235.
39 Duncan, R., Milburn, S.C. and Hershey, J.W. (1987) Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J. Biol. Chem., 262, 380–388.
40 Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E. and Hagerman, P.J. (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet., 66, 6–15.[Web of Science][Medline]
41 De Boulle, K., Verkerk, A.J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy, B., Van den Bos, F., de Graaff, E., Oostra, B.A. and Willems, P.J. (1993) A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat. Genet., 3, 31–35.[Web of Science][Medline]
42 Ashley, C.T.,Jr., Wilkinson, K.D., Reines, D. and Warren, S.T. (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science, 262, 563–566.
43 Feng, Y., Zhang, F., Lokey, L.K., Chastain, J.L., Lakkis, L., Eberhart, D. and Warren, S.T. (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science, 268, 731–734.
44 Tassone, F., Hagerman, R.J., Chamberlain, W.D. and Hagerman, P.J. (2000) Transcription of the FMR1 gene in individuals with fragile X syndrome. Am. J. Med. Genet., 97, 195–203.[Web of Science][Medline]
45 Lewis, H.A., Musunuru, K., Jensen, K.B., Edo, C., Chen, H., Darnell, R.B. and Burley, S.K. (2000) Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. Cell, 100, 323–332.[Web of Science][Medline]
46 Feng, Y., Absher, D., Eberhart, D.E., Brown, V., Malter, H.E. and Warren, S.T. (1997) FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell, 1, 109–118.
47 Raca, G., Siyanova, E. and Mirkin, S. (2000) Janus effects of premutation size CGG repeats on gene expression. Am. J. Hum. Genet., 67, 366.
48 Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.P. and Mandel, J.L. (1993) The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat. Genet., 4, 335–340.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. L. Ludwig, C. Raske, F. Tassone, D. Garcia-Arocena, J. W. Hershey, and P. J. Hagerman Translation of the FMR1 mRNA is not influenced by AGG interruptions Nucleic Acids Res., September 14, 2009; (2009) gkp713v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hashem, J. N. Galloway, M. Mori, R. Willemsen, B. A. Oostra, R. Paylor, and D. L. Nelson Ectopic expression of CGG containing mRNA is neurotoxic in mammals Hum. Mol. Genet., July 1, 2009; 18(13): 2443 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iwahashi, F. Tassone, R. J. Hagerman, D. Yasui, G. Parrott, D. Nguyen, G. Mayeur, and P. J. Hagerman A Quantitative ELISA Assay for the Fragile X Mental Retardation 1 Protein J. Mol. Diagn., July 1, 2009; 11(4): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ofer, P. Weisman-Shomer, J. Shklover, and M. Fry The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA Nucleic Acids Res., May 1, 2009; 37(8): 2712 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Hagerman, E. Berry-Kravis, W. E. Kaufmann, M. Y. Ono, N. Tartaglia, A. Lachiewicz, R. Kronk, C. Delahunty, D. Hessl, J. Visootsak, et al. Advances in the Treatment of Fragile X Syndrome Pediatrics, January 1, 2009; 123(1): 378 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-F. Richard, A. Kerrest, and B. Dujon Comparative Genomics and Molecular Dynamics of DNA Repeats in Eukaryotes Microbiol. Mol. Biol. Rev., December 1, 2008; 72(4): 686 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Usdin The biological effects of simple tandem repeats: Lessons from the repeat expansion diseases Genome Res., July 1, 2008; 18(7): 1011 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Ladd, L. E. Smith, N. A. Rabaia, J. M. Moore, S. A. Georges, R. S. Hansen, R. J. Hagerman, F. Tassone, S. J. Tapscott, and G. N. Filippova An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals Hum. Mol. Genet., December 15, 2007; 16(24): 3174 - 3187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Sofola, P. Jin, J. Botas, and D. L. Nelson Argonaute-2-dependent rescue of a Drosophila model of FXTAS by FRAXE premutation repeat Hum. Mol. Genet., October 1, 2007; 16(19): 2326 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khateb, P. Weisman-Shomer, I. Hershco-Shani, A. L. Ludwig, and M. Fry The tetraplex (CGG)n destabilizing proteins hnRNP A2 and CBF-A enhance the in vivo translation of fragile X premutation mRNA Nucleic Acids Res., September 27, 2007; 35(17): 5775 - 5788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Garcia-Alegria, B. Ibanez, M. Minguez, M. Poch, A. Valiente, A. Sanz-Parra, C. Martinez-Bouzas, E. Beristain, and M.-I. Tejada Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models RNA, May 1, 2007; 13(5): 756 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tassone, A. Beilina, C. Carosi, S. Albertosi, C. Bagni, L. Li, K. Glover, D. Bentley, and P. J. Hagerman Elevated FMR1 mRNA in premutation carriers is due to increased transcription RNA, April 1, 2007; 13(4): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Z Loesch, Q. M Bui, R. M Huggins, R. J Mitchell, R. J Hagerman, and F. Tassone Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats J. Med. Genet., March 1, 2007; 44(3): 200 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Krasilnikova, M. L. Kireeva, V. Petrovic, N. Knijnikova, M. Kashlev, and S. M. Mirkin Effects of Friedreich's ataxia (GAA)n{middle dot}(TTC)n repeats on RNA synthesis and stability Nucleic Acids Res., February 28, 2007; 35(4): 1075 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Osborne and C. A. Thornton RNA-dominant diseases Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R162 - R169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Rietveld, M. K. Ikram, J. R. Vingerling, A. Hofman, H. A.P. Pols, S. W.J. Lamberts, P. T.V.M. de Jong, C. M. van Duijn, and J. A.M.J.L. Janssen An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes, August 1, 2006; 55(8): 2387 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greco, R. F. Berman, R. M. Martin, F. Tassone, P. H. Schwartz, A. Chang, B. D. Trapp, C. Iwahashi, J. Brunberg, J. Grigsby, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS) Brain, January 1, 2006; 129(1): 243 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Iwahashi, D. H. Yasui, H.-J. An, C. M. Greco, F. Tassone, K. Nannen, B. Babineau, C. B. Lebrilla, R. J. Hagerman, and P. J. Hagerman Protein composition of the intranuclear inclusions of FXTAS Brain, January 1, 2006; 129(1): 256 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Arocena, C. K. Iwahashi, N. Won, A. Beilina, A. L. Ludwig, F. Tassone, P. H. Schwartz, and P. J. Hagerman Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells Hum. Mol. Genet., December 1, 2005; 14(23): 3661 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lim, A. B. Booker, T. Luo, T. Williams, Y. Furuta, O. Lagutin, G. Oliver, T. D. Sargent, and J. R. Fallon AP-2{alpha} selectively regulates fragile X mental retardation-1 gene transcription during embryonic development Hum. Mol. Genet., July 15, 2005; 14(14): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Mulvihill, K. N. Edamura, K. A. Hagerman, C. E. Pearson, and Y.-H. Wang Effect of CAT or AGG Interruptions and CpG Methylation on Nucleosome Assembly upon Trinucleotide Repeats on Spinocerebellar Ataxia, Type 1 and Fragile X Syndrome J. Biol. Chem., February 11, 2005; 280(6): 4498 - 4503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Napierala, D. Michalowski, M. de Mezer, and W. J. Krzyzosiak Facile FMR1 mRNA structure regulation by interruptions in CGG repeats Nucleic Acids Res., January 19, 2005; 33(2): 451 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pietrobono, E. Tabolacci, F. Zalfa, I. Zito, A. Terracciano, U. Moscato, C. Bagni, B. Oostra, P. Chiurazzi, and G. Neri Molecular dissection of the events leading to inactivation of the FMR1 gene Hum. Mol. Genet., January 15, 2005; 14(2): 267 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Moore, E. M. Daly, F. Tassone, C. Tysoe, N. Schmitz, V. Ng, X. Chitnis, P. McGuire, J. Suckling, K. E. Davies, et al. The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy Brain, December 1, 2004; 127(12): 2672 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Welt, P. C. Smith, and A. E. Taylor Evidence of Early Ovarian Aging in Fragile X Premutation Carriers J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4569 - 4574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Smith, B. Coffee, and D. Reines Occupancy and synergistic activation of the FMR1 promoter by Nrf-1 and Sp1 in vivo Hum. Mol. Genet., August 1, 2004; 13(15): 1611 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Li, A. B. Korol, T. Fahima, and E. Nevo Microsatellites Within Genes: Structure, Function, and Evolution Mol. Biol. Evol., June 1, 2004; 21(6): 991 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Tassone, R J Hagerman, D Garcia-Arocena, E W Khandjian, C M Greco, and P J Hagerman Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome J. Med. Genet., April 1, 2004; 41(4): e43 - e43. [Full Text] [PDF]
|
|
|
|
|
|
A. Beilina, F. Tassone, P. H. Schwartz, P. Sahota, and P. J. Hagerman Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element Hum. Mol. Genet., March 1, 2004; 13(5): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-S. Chen, F. Tassone, P. Sahota, and P. J. Hagerman The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter Hum. Mol. Genet., December 1, 2003; 12(23): 3067 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Oostra and R. Willemsen A fragile balance: FMR1 expression levels Hum. Mol. Genet., October 15, 2003; 12(90002): R249 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gersak, H. Meden-Vrtovec, and B. Peterlin Fragile X premutation in women with sporadic premature ovarian failure in Slovenia Hum. Reprod., August 1, 2003; 18(8): 1637 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Willemsen, M. Hoogeveen-Westerveld, S. Reis, J. Holstege, L.-A. W.F.M. Severijnen, I. M. Nieuwenhuizen, M. Schrier, L. van Unen, F. Tassone, A. T. Hoogeveen, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome Hum. Mol. Genet., May 1, 2003; 12(9): 949 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pietrobono, M. G. Pomponi, E. Tabolacci, B. Oostra, P. Chiurazzi, and G. Neri Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine Nucleic Acids Res., July 15, 2002; 30(14): 3278 - 3285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Tarleton, A Kenneson, A K Taylor, K Crandall, R Fletcher, R Casey, P S Hart, D Hatton, G Fisch, and S T Warren A single base alteration in the CGG repeat region of FMR1: possible effects on gene expression and phenotype J. Med. Genet., March 1, 2002; 39(3): 196 - 200. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||